Technical Analysis for AEZS - Aeterna Zentaris Inc

Grade Last Price % Change Price Change
grade A 5.57 -2.28% -0.130
AEZS closed down 2.28 percent on Friday, March 22, 2019, on 1.25 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AEZS trend table...

Date Alert Name Type % Chg
Mar 22 Bearish Engulfing Bearish 0.00%
Mar 22 Stochastic Sell Signal Bearish 0.00%
Mar 22 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 New 52 Week Closing High Bullish -2.28%
Mar 21 New 52 Week High Strength -2.28%
Mar 21 Overbought Stochastic Strength -2.28%
Mar 20 Overbought Stochastic Strength -0.36%
Mar 20 Upper Bollinger Band Touch Strength -0.36%
Mar 19 New 52 Week Closing High Bullish -0.71%

Older signals for AEZS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Articles Biotechnology Biopharmaceutical Drug Development Life Sciences Peptides
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.75
52 Week Low 1.5
Average Volume 34,094
200-Day Moving Average 3.4683
50-Day Moving Average 5.2054
20-Day Moving Average 5.2475
10-Day Moving Average 5.34
Average True Range 0.2691
ADX 17.92
+DI 23.7161
-DI 20.0011
Chandelier Exit (Long, 3 ATRs ) 4.9427
Chandelier Exit (Short, 3 ATRs ) 5.5073
Upper Bollinger Band 5.7744
Lower Bollinger Band 4.7206
Percent B (%b) 0.81
BandWidth 20.081944
MACD Line 0.1116
MACD Signal Line 0.0574
MACD Histogram 0.0541
Fundamentals Value
Market Cap 89.74 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -3.26
Price-to-Sales 42.62
Price-to-Book 5.01
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.095
Resistance 3 (R3) 6.080 5.890 6.008
Resistance 2 (R2) 5.890 5.756 5.898 5.978
Resistance 1 (R1) 5.730 5.674 5.635 5.745 5.949
Pivot Point 5.540 5.540 5.493 5.548 5.540
Support 1 (S1) 5.380 5.406 5.285 5.395 5.191
Support 2 (S2) 5.190 5.324 5.198 5.162
Support 3 (S3) 5.030 5.190 5.133
Support 4 (S4) 5.045